medigraphic.com

2016, Número 6

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2016; 54 (6)


Uso de quimioterapia durante el embarazo

Benardete-Harari DN, Kershenovich-Gersson J, MerazÁvila D, Galnares-Olalde JA, Olaya-Guzmán EJ

Idioma: Español
Referencias bibliográficas: 39
Paginas: 752-758
Archivo PDF: 457.08 Kb.


RESUMEN

La presencia de tumores malignos durante la gestación complica tanto el manejo como el propio embarazo, ya que cualquier intervención diagnóstica o terapéutica puede conllevar riesgos que puedan generar efectos nocivos para la madre o para el feto. Los riesgos que tiene un feto sometido a la administración de la terapia citotóxica se correlacionan directamente con la edad gestacional y con el tiempo de la exposición intrauterina a la misma. El tratamiento antineoplásico busca dos objetivos principales; el primero es el control local por medio de cirugía complementada con radioterapia; el segundo busca erradicar la enfermedad sistémica a través de quimioterapia, inmunoterapia, hormonoterapia o terapias blanco.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ERM, et al. Obstetrics: Normal and Problem Pregnancies. Sixth edition. Philadelphia, PA, USA: Elsevier; 2012. pp. 1256-1276.

  2. Gerson R, Serrano A, Flores VF, Villalobos A. Quimioterapia en cáncer durante el embarazo. Anales Medicos. 2006;61:29-32.

  3. DeVita VT, LawrenceTS, Rosenberg SA. Cancer: Principles & Practice of Oncology. 8th Edition. Philadelphia, PA, USA: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.

  4. Cohn D, Ramaswamy B, Blum K. Malignancy and pregnancy. In: Creasy RK, Resnik R, Iams JD, et al. (eds.). Creasy & Resnik’s maternal fetal medicine: Principles and practice. Sixth edition. Philadelphia, PA, USA: Saunders; 2009. pp. 885-904.

  5. Muñoz MC. Uso de Quimioterapia en el embarazo (Caso clínico y revisión bibliográfica). Revista Medica de Costa Rica y Centroamérica. 2010;LXVII(592):207-10.

  6. Perry MC. The chemotherapy source book. Fourth edition. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2008.

  7. Amant F, Loibl S, Neven P, Van Calsteren K. Breast Cancer During Pregnancy. Lancet. 2012;379:570-9.

  8. Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG. Williams Ginecología. Neoplasias. McGraw- Hill. 2008;13: 1193-1206.

  9. Gao B, Yeap S, Clements A, Balakrishnar B, Wong M, Gurney H. Evidence for therapeutic drug monitoring of targeted anticancer therapies. J Clin Oncol. 2012 Nov 10;30(32):4017-25. doi: 10.1200/ JCO.2012.43.5362.

  10. Tubiana M. Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol. 1989;28:113-21.

  11. Nygren P; SBU-group. Swedish Council on Technology Assessment in Health Care. What is cancer chemotherapy? Acta Oncol. 2001;40(2-3):166-74.

  12. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer. 1996;32A:912-9.

  13. Godoy-Rivera LM. Biología Molecular en cáncer. Clínicas Oncológicas de Iberoamérica. P DESA; 2008. pp. 29-36.

  14. Jones PA. Overview of cancer epigenetics. Semin Hematol. 2005 Jul;42(3 Suppl 2):S3-8.

  15. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009 Jan;7(1):99-108.

  16. Frei E 3rd, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980 Oct;69(4):585-94.

  17. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996 Sep;14(9):2590-611.

  18. Gurney H. How to calculate the dose of chemotherapy. Br J Cancer. 2002 Apr 22;86(8):1297-302.

  19. Gurney H. I don’t underdose my patients... do I? Lancet Oncol. 2005;6:637-8.

  20. Marchetti S, Schellens JHM. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer. 2007 Aug 28; 97(5): 577- 81. doi: 10.1038/sj.bjc.6603925

  21. Baker SD, Verweij J, Rowinsky EK, Donehower RC, Schellens JH, Grochow LB, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. 2002 Dec 18;94(24):1883-8.

  22. Theriault R, Hahn K. Management of breast cancer in pregnancy. Curr Oncol Rep. 2007 Jan;9(1):17-21.

  23. Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am. 2005 Dec;32(4):627-40.

  24. Food and Drug Administration. Guidance for industry: Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy. Disponible en volunteers.www.fda.gov/downloads/ Drugs/Guidance/UCM078932.pdf

  25. Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, et al. Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol. 2012 Aug;94(8):626-50. doi: 10.1002/bdra.23063.

  26. Mir O, Berveiller P, Ropert S, Goffinet F, Goldwasser F. Use of platinum derivatives during pregnancy. Cancer. 2008 Dec 1;113(11):3069-74. doi: 10.1002/ cncr.23935.

  27. Cancer Care Ontario, Cancer in young adults in Canada. Toronto: Cancer Care Ontario; 2006. May 2006.

  28. Santucci AK, Gold MA, Akers AY, Borrero S, Schwarz EB. Women’s perspectives on counseling about risks for medication-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2009;88:64-9.

  29. Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302-12.

  30. Azim HA, Peccatori FA. Managing cancer during pregnancy: what evidence do we have? Pol Arch Med Wewn. 2011;121:29-34.

  31. Leslie KK. Chemotherapy and pregnancy. Clin Obstet Gynecol. 2002;45(1):153-64.

  32. Koren G. Fetal risks of maternal pharmacotherapy: identifying signals. Handb Exp Pharmacol. 2011;205:285-94.

  33. Buhimschi CS, Weiner CP. Medications in pregnancy and lactation: part 1. Teratology. Obstet Gynecol. 2009;113(1):166-88.

  34. Kirshon B, Wasserstrum N, Willis R, Herman GE, Mc- Cabe ER. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol. 1988;72(3 Pt2):462-4.

  35. Missailidis S (ed.). Anticancer therapeutics. First edition. Chichester, West Sussex, UK: John Wiley & Sons; 2008.

  36. Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013 Mar;35(3):263-80.

  37. Cole S, Kantarjian H, Ault P, Cortes JE. Successful completion of pregnancy in patient with CML without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9(4):324-7.

  38. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.

  39. Pentheroudakis G. Cancer and pregnancy. Ann Oncol. 2008;19(5):v38-v39.




2020     |     www.medigraphic.com